Company News • Endpoint Arena

News Updates

Thu, May 28, 2026

1 updates

10:00 AM

Jaguar Health Research in Ethnobotanical Medicine Helps Advance Crofelemer Development for Genetically Defined Rare Congenital Gastrointestinal Disorders

Crofelemer delayed-release tablets are Jaguar's FDA-approved prescription drug under botanical guidance ("botanical drug") derived from the Croton lechleri tree. Crofelemer, in a novel liquid formulation, is being developed as the potential first oral adjunctive therapy for Intestinal Failure (IF)

Presentation / AbstractESPGHAN late-breaking abstracts Thu, May 28, 2026jaguar.health

Wed, May 27, 2026

1 updates

JAGX

9:00 AM

Jaguar Health Compliant with Nasdaq Bid Price Rule

JAGX's securities continue to be listed and traded on Nasdaq SAN FRANCISCO, CA / ACCESS Newswire / May 27, 2026 / Jaguar Health, Inc. ( NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that on May 26, 2026, the Company received formal notice from The Nasdaq Stock Market LLC ("Nasdaq") that

jaguar.health

Wed, May 20, 2026

2 updates

JAGX

4:40 PM

Jaguar Health Reports First Quarter 2026 Financials

Net revenue increased 816% in Q1 2026 vs. Q1 2025, and increased 527% in Q1 2026 vs. Q4 2025, buoyed by license of U.S. commercial rights for Mytesi ® and Canalevia ® -CA1 Company continues its focus on crofelemer development efforts for rare-disease intestinal failure indications; two crofelemer

Presentation / AbstractESPGHAN abstract release Mon, Jun 1, 2026jaguar.health

JAGX

9:00 AM

Jaguar Health to Hold Investor Webcast May 26 Regarding Q1 2026 Financials & Corporate Updates; Jaguar CEO Lisa Conte Presenting May 28 at Lytham Partners Spring 2026 Investor Conference

Click here to register for Jaguar's May 26 webcast; Click here to register for May 28 virtual presentation at Lytham Partners Conference Company plans to file its Earnings Report on May 20, 2026 on Form 10-Q for the quarter ended March 31, 2026 SAN FRANCISCO, CA / ACCESS Newswire / May 20, 2026 /

jaguar.health

Tue, May 19, 2026

1 updates

JAGX

9:00 AM

Jaguar Health Announces Active Treatment Only Continuation of Pivotal Multicenter Clinical Trial in Pediatric Patients with Microvillus Inclusion Disease (MVID) to Support a New Drug Application (NDA) for Liquid Oral Crofelemer

First MVID patient enters the active treatment only extension phase after completion of randomized double-blind crossover period to evaluate longer-term safety and efficacy with liquid oral crofelemer as adjunctive treatment for MVID, an ultrarare pediatric disease with a lethal natural history and

Presentation / AbstractESPGHAN presentation Mon, Jun 1, 2026jaguar.health

Fri, May 8, 2026

1 updates

JAGX

9:00 AM

Jaguar Health Regains Compliance with Nasdaq's Publicly Held Shares Requirement and Receives Additional Extension, Until May 18, 2026, to Demonstrate Compliance with Nasdaq's Bid Price Rule

SAN FRANCISCO, CA / ACCESS Newswire / May 8, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today provided an update on the status of the Company's listing on The Nasdaq Stock Market ("Nasdaq"). On May 6, 2026, Jaguar received a decision letter from the Nasdaq Hearings Panel

jaguar.health

Wed, May 6, 2026

1 updates

JAGX

9:00 AM

Jaguar Health Announces Preliminary Discussion with FDA to Evaluate Breakthrough Therapy Designation for Crofelemer for Treatment of Microvillus Inclusion Disease (MVID)

Pediatric patients with Intestinal Failure (IF) due to MVID, an ultrarare congenital disorder with lethal natural history, that has no available therapies and needs lifelong total Parenteral Support (PS), could benefit from expedited development of oral crofelemer via Breakthrough Therapy

jaguar.health

Mon, May 4, 2026

1 updates

JAGX

8:30 AM

Jaguar Health Expands Neonorm Franchise with Introduction of Neonorm Dog for Companion Animal Gut Health

Neonorm Dog extends Jaguar's existing Neonorm product franchise beyond foals and calves to provide dog owners with access to a plant-based product designed to support normal stool formation, gut hydration, and bowel health Expansion builds on Jaguar's focus on sustainably derived, plant-based

jaguar.health

Wed, Apr 29, 2026

1 updates

JAGX

8:30 AM

Jaguar Health Announces Statistically Significant Results from Effectiveness Trial of Crofelemer (FDA Approved Canalevia-CA1) for Treatment of Chemotherapy-Induced Diarrhea in Dogs

Company Advances Towards Full FDA Approval of Crofelemer for Chemotherapy-Induced Diarrhea SAN FRANCISCO, CA / ACCESS Newswire / April 29, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) today announced topline results from the completion of its effectiveness trial of crofelemer (FDA

jaguar.health

Mon, Apr 27, 2026

1 updates

JAGX

9:00 AM

Jaguar Health Granted Extension Until May 15, 2026, to Demonstrate Compliance with Nasdaq's Bid Price Rule; Company Announces Reverse Stock Split

Reverse split approved at April 2026 Special Meeting of Stockholders Shares of Jaguar Health common stock to begin trading on split-adjusted basis on April 30, 2026 SAN FRANCISCO, CA / ACCESS Newswire / April 27, 2026 / Jaguar Health, Inc. ( Nasdaq:JAGX) ("Jaguar" or the "Company") today announced

jaguar.health

Fri, Apr 24, 2026

1 updates

JAGX

8:30 AM

Jaguar Health Announces Acceptance of two Late-Breaking Abstracts for Liquid Oral Crofelemer Treatment of Intestinal Failure in Pediatric Patients at the European Society for Pediatric Gastroenterology, Hepatology & Nutrition (ESPGHAN)

Intestinal Failure (IF) occurs in patients with an ultrarare congenital enteropathy due to microvillus inclusion disease (MVID) and/or short bowel syndrome (SBS) Jaguar has received orphan drug designations for MVID & SBS in the US and EU Jaguar has also completed enrollment of pediatric MVID

Presentation / Abstractjaguar.health

Mon, Apr 20, 2026

1 updates

JAGX

4:15 PM

Jaguar Health Reports Approval of All Proposals at April 2026 Special Meeting of Stockholders

SAN FRANCISCO, CA / ACCESS Newswire / April 20, 2026 / Jaguar Health, Inc. ( NASDAQ:JAGX) ("Jaguar" or the "Company") today announced the voting results of the Company's Special Meeting of Stockholders held on April 20, 2026 (the "Special Meeting"). Five proposals were submitted to and approved by

jaguar.health

Mon, Apr 13, 2026

1 updates

JAGX

8:30 AM

Artificial Intelligence (AI) Platforms Could Enhance Jaguar Health's Development and Anticipated Commercialization of Crofelemer for Rare Disease Intestinal Failure (IF) Programs

Global Market for Short Bowel Syndrome, Including Intestinal Failure (IF), Estimated to Reach $8.0 Billion by 2033 1 AI data mining of real world clinical and symptom manifestation is beneficial in the development of credible links between genetics, histopathology, and disease progression

jaguar.health

Thu, Apr 9, 2026

1 updates

JAGX

8:15 PM

Reminder: Jaguar Health to Host Investor Webcast at 8:30 am Eastern on Friday, April 10, 2026 Regarding Q4 2025 Financials and Company Updates

Click here to register SAN FRANCISCO, CA / ACCESS Newswire / April 9, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) Participation Instructions for Webcast When: Friday, April 10, 2026 at 8:30 a.m. Eastern Participant Registration & Access Link: Click Here Replay Instructions for Webcast Replay of the

jaguar.health

Wed, Apr 8, 2026

1 updates

JAGX

8:30 AM

Jaguar Health Completes Effectiveness Trial to Support FDA Approved Crofelemer for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs

Topline results expected within a month and may complement positive results of a study of crofelemer for treatment of cancer therapy-induced diarrhea (CTD) in dogs receiving neratinib - a targeted tyrosine kinase inhibitor (TKI) SAN FRANCISCO, CA / ACCESS Newswire / April 8, 2026 / Jaguar Health,

jaguar.health

Tue, Apr 7, 2026

1 updates

JAGX

8:30 AM

Jaguar Health Reports 2025 Financials

Net revenue increase of 5% in Q4 2025 vs. Q3 2025 Jaguar received an up-front payment of $16Mof non-dilutive capital in January 2026 upon entering U.S. license agreement with Future Pak for Mytesi ® and Canalevia ® -CA1 - Jaguar's commercialized crofelemer drugs - with an additional $2 million due

jaguar.health

Thu, Apr 2, 2026

1 updates

JAGX

9:00 AM

Jaguar Health Family Company Napo Pharmaceuticals Co-Sponsoring Pediatric Gastroenterology Conference: Elite Ped-GI Congress

Jaguar continues its sharp strategic focus on its global development program for crofelemer for rare-disease intestinal failure (IF) indications; all patients with microvillus inclusion disease (MVID) suffer from IF, as do a significant proportion of patients with short bowel syndrome (SBS).

Presentation / Abstractjaguar.health

Wed, Mar 18, 2026

1 updates

JAGX

9:00 AM

FDA Feedback Supports Extension Phase for Jaguar Health's Clinical Trial of Crofelemer for Treatment of Microvillus Inclusion Disease (MVID)

MVID has a lethal natural history requiring life-sustaining parenteral support (PS), which includes total parenteral nutrition (TPN), which is associated with significant toxicities; PS reduction could potentially reduce co-morbidities and improve clinical benefit, as no approved therapies exist

jaguar.health

Mon, Mar 16, 2026

1 updates

JAGX

9:00 AM

Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, Initiates Preclinical Study of Coca for Appetite Suppression

Whole leaf coca extract under evaluation is Magdalena's drug candidate for post-GLP-1 weight loss management SAN FRANCISCO, CA / ACCESS Newswire / March 16, 2026 / Jaguar Health, Inc. ( NASDAQ:JAGX) ("Jaguar") today announced that Magdalena Biosciences ("Magdalena"), a US-based joint venture formed

jaguar.health